<DOC>
	<DOCNO>NCT00941460</DOCNO>
	<brief_summary>For patient progressive recurrent glioblastoma standard therapy . One strategy re-exposure temozolomide high dose . This increase dose do 2 regimen . Aim study compare 2 dose regimen concern toxicity . In study arm A patient receive temozolomide one week , follow week without temozolomide . In study arm B patient receive temozolomide three week , follow week without temozolomide . The regimen le toxic select evaluation .</brief_summary>
	<brief_title>Comparison Two Dosing Regimens Temozolomide Patients With Progressive Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Progressive recurrent glioblastoma document MRI earlier 180 day first surgery glioblastoma earlier 90 day completion radiotherapy . Histological diagnosis glioblastoma Tissue available determination MGMT promoter methylation primary tumor recurrent tumor patient undergoes surgical procedure recurrence prior study entry . Prior treatment temozolomide administer concomitantly radiotherapy least two cycle ( 5/28 ) adjuvant treatment Informed consent Age 1880 year Karnofsky performance score &gt; 50 % Neutrophil count &gt; 1 500/µl Platelet count &gt; 100 000/µl Hemoglobin &gt; 10 g/dl Serum creatinin &lt; 1.5fold upper normal range ASAT ALAT &lt; 3fold upper normal range unless attribute anticonvulsant Alkaline phosphatase &lt; 3fold upper normal range Women childbearing potential must negative serum pregnancy test ≤14 day prior study enrollment Willingness apply contraception accord local requirement ( state patient information ) Progressive recurrent glioblastoma document MRI earlier 180 day first surgery glioblastoma earlier 90 day completion radiotherapy . Treatment chemotherapy temozolomide accord schedule EORTC NCIC trial ( Stupp et al . N Engl J Med 2005 ; 352:987996 ) except adjuvant start dose 200 mg/m2 6 cycle adjuvant temozolomide allow Prior systemic local treatment DNAdamaging agent , tyrosine kinase inhibitor antiangiogenic agent cancer Allergy intolerability temozolomide Unable undergo MRI Past medical history disease poor prognosis , e.g . severe coronary heart disease , severe diabetes , immune deficiency , residual deficit stroke , severe mental retardation HIV infection Pregnancy Breast feeding Treatment within clinical trial parallel treatment phase current study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>progressive recurrent glioblastoma</keyword>
	<keyword>temozolomide</keyword>
	<keyword>dose intensification</keyword>
	<keyword>comparison two dosing regimen</keyword>
</DOC>